Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. Proton pump inhibitor use associated with an increased risk of gout
 
  • Details
Options

Proton pump inhibitor use associated with an increased risk of gout

Other Title
A population-based case–control study
Journal
International Journal of Rheumatic Diseases
Date Issued
2023-09-01
Author(s)
JING-YANG HUANG  
JAMES CHENG-CHUNG WEI  
DOI
10.1111/1756-185X.14834
URI
https://www.scopus.com/pages/publications/85165430407
https://scholars.csmu.edu.tw/handle/123456789/25674
Abstract
Objectives: In previous reports, proton pump inhibitor (PPI) use increased the risk of gout. However, there is no epidemiological study investigating this association. We aimed to examine the potential impact of PPI treatment on the risk of developing gout. Methods: A population-based case–control study was performed using a Longitudinal Health Insurance Database 2000 from Taiwan (population 23 million). We identified gout cases and non-gout controls through propensity score matching at 1:1, which was matched by sex and age. We used a conditional logistic regression model to estimate an odds ratio and 95% confidence intervals (CI) for gout population versus controls. Results: Esomeprazole increased the risk of gout after adjusting confounding variables (adjusted odds ratio [aOR] 1.3; 95% CI 1.0–1.6). The risk of gout was highest within 30 days of PPI treatment (aOR 1.7; 95% CI 1.4–1.9) and attenuated thereafter. The risk of gout was increased among female users of PPI compared with male users (aOR 2.2; 95% CI 1.7–2.8). The aOR of gout in people with PPI use was higher in middle-aged individuals (41–60 years: aOR 2.1; 95% CI 1.7–2.7) than in the older group (≥60 years: aOR 1.8; 95% CI 1.5–2.2). Conclusions: Our findings provide population-level evidence for the hypothesis that PPI treatment is positively associated with the risk of developing gout. Further research on the mechanism underlying this association is warranted.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback